Drug Database
Back to search

Poland· PL-100408465

Tegsedi

A inotersen product containing inotersenum, registered in Poland by Akcea Therapeutics Ireland Ltd.. The same ATC class is registered in 9 of our 19 countries.

ATC N07XX15

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedTegsediATCN07XX15REGISTER NO.PL-100408465PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about inotersenumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Inotersen is registered in 9 of 19 countries.

Countries holding a registration under ATC N07XX15 (inotersen), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search inotersen products by name

Inotersen · ATC N07XX15

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Inotersenum
Manufacturer
Akcea Therapeutics Ireland Ltd.
Country
Poland (PL)
ATC code
N07XX15
ATC class
Inotersen
Defined daily dose
41 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05397216000340
  • gtin
    05397216000111
  • gtin
    05397216000166

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

169 interactions on record for inotersen.

Graded by severity as the source publishes them — 143 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check inotersen against other medicinesHow interaction checks work

Inotersen · interactions on record

169 records

  • 143 severe
  • 26 moderate

Most severe, free to view

  • HeparinB01AB01severe
  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Inotersen in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All inotersen products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tegsedi
  • Liechtenstein · Tegsedi
  • Norway · Tegsedi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2d5d07c2-6647-410d-b50c-6d3d80c64e71
GET /v1/drugs/2d5d07c2-6647-410d-b50c-6d3d80c64e71?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "284 mg",
  "packaging": "Rpz ¦ EU/1/18/1296/001 ¦ 129091\n1 amp.-strzyk. 1,5 ml\n05397216000340 ¦ Rpz ¦ EU/1/18/1296/002 ¦ 129092\n4 amp.-strzyk. 1,5 ml\n¦ UR/Z/4b/174/22 - 05397216000111 ¦ UR/Z/4b/070/23 - 05397216000166",
  "substance": "Inotersenum 284 mg",
  "common_name": "Inotersenum",
  "pl_product_id": "100408465",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about inotersen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console